Granted Patent
B2
US 12,303,480 · App. 18/506,051 · Granted May 20, 2025
Methods of treatment of cholestatic diseases
Assignee:
Genfit
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Claims (15)
1. A method for improving lipid parameters in a subject having primary biliary cholangitis (PBC), the method comprising orally administering to the subject a composition comprising elafibranor or a pharmaceutically acceptable salt of elafibranor at a dose between 70 mg and 130 mg per administration.
2. The method of claim 1 , wherein the treatment improves triglyceride levels in the subject.
3. The method of claim 1 , wherein the treatment improves low density lipoprotein-cholesterol (LDL-cholesterol) level in the subject.
4. The method of claim 1 , wherein the treatment improves high density lipoprotein-cholesterol (HDL-cholesterol) level in the subject.
5. The method of claim 1 , wherein the composition comprises elafibranor.
6. The method of claim 1 , wherein said composition is formulated in a form selected from the group consisting of a gel, an oil, a pill, a tablet, a powder, a gel cap, a capsule, and a galenic form or device assuring a prolonged and/or slow release.
7. The method of claim 6 , wherein said composition is formulated in a form of a tablet.
8. The method of claim 1 , wherein elafibranor is administered once a day.
9. The method of claim 1 , wherein the administration dose is of 80 mg per administration.
10. The method of claim 1 , wherein the administration dose is of 120 mg per administration.
11. The method of claim 1 , wherein the subject having primary biliary cholangitis (PBC) has an inadequate response to ursodeoxycholic acid.
12. The method of claim 1 , further comprising administering to the subject another anti-cholestatic agent.
13. The method of claim 11 , wherein the other anti-cholestatic agent is ursodeoxycholic acid (UDCA).
14. The method according to claim 1 , the method comprising orally administering elafibranor at a dose of 80 mg per administration and ursodeoxycholic acid (UDCA), to the subject.
15. The method according to claim 1 , the method comprising orally administering elafibranor at a dose of 80 mg per administration and ursodeoxycholic acid (UDCA), to a subject having primary biliary cholangitis (PBC) and an inadequate response to UDCA.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 8, 2024
From: HANF, REMY
To: GENFIT
Reel/Frame 067037/0141 →
Priority Claims (1)
EP 16305381
· Mar 31, 2016
· regional
Continuity (4)
Continuation
16090415
References Cited (95)
US 8772342B2
· Darteil et al.
· 2014
[cited by applicant]
US 20070197606A1
· Burczynski et al.
· 2007
[cited by applicant]
US 20230052189A1
· Petit et al.
· 2023
[cited by applicant]
US 20230165821A1
· Roudot
· 2023
[cited by applicant]
US 20240216312A1
· Legry et al.
· 2024
[cited by applicant]
US 20240216313A1
· Legry et al.
· 2024
[cited by applicant]
CN 101461819A
· 2009
[cited by applicant]
EP 2982667A1
· 2016
[cited by applicant]
WO 2005000196A2
· 2005
[cited by applicant]
WO 2007147880A1
· 2007
[cited by applicant]
WO 2008087366A2
· 2008
[cited by applicant]
WO 2008087367A2
· 2008
[cited by applicant]
WO 2012115987A2
· 2012
[cited by applicant]
WO 2014062938A1
· 2014
[cited by applicant]
WO 2016127019A2
· 2016
[cited by applicant]
WO 2016154258A1
· 2016
[cited by applicant]
WO 2017010399A1
· 2017
[cited by applicant]
WO 2017167935A1
· 2017
[cited by applicant]
WO 2018060372A1
· 2018
[cited by applicant]
WO 2018193006A1
· 2018
[cited by applicant]
WO 2019053582A1
· 2019
[cited by applicant]
WO 2019067373A1
· 2019
[cited by applicant]
WO 2021059023A1
· 2021
[cited by applicant]
Anonymous, “GFT505 Broadens Its Therapeutic Potential,” URL:http://hugin.info/143426/R/1672617/544056.pdf XP055866259 [retrieved on Nov. 26, 2021], Jan. 24, 2013.
[cited by applicant]
Anonymous, “Press Release GENFIT Provides Pipeline Update and Launch of New Clinical,” URL:https://ml-eu.globenewswire.com/Resource/Download/f248612c-5b0d-41a3-ba8d-f95a8c910e59 XP055866591 [retrieved on Nov. 26, 2021],…
[cited by applicant]
Araujo, et al., “PPAR gamma activation protects the brain against microvascular dysfunction in sepsis,” Microvascular Research, vol. 84, No. 2, p. 218-221, Sep. 1, 2012.
[cited by applicant]
Baschet, et al., “Cost-Effectiveness Analysis of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis (PBC) Patients With Inadequate Response or Intolerance to Ursodeoxycholic Acid (UDCA) In France,” Value …
[cited by applicant]
Benedetta, et al., “The challenges of primary biliary cholangitis: What is new and what needs to be done,” Journal of Autoimmunity, 105, 2019.
[cited by applicant]
Bloomfield, et al., “Routine Ertapenem Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy does Not Select for Carbapenem Resistant Organisms: A Prospective Cohort Study”, Journal of Urology, vol. 198, No. 2, …
[cited by applicant]
Bougarne, et al., “Molecular Actions of PPAR[alpha] in Lipid Metabolism and Inflammation,” US vol. 39, No. 5, p. 760-802, Endocrine Reviews, Retrieved from the Internet: URL:https://academic.oup.com/edrv/article-pdf/39/…
[cited by applicant]
Boyer-Diaz, et al., “Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease,” Journal of Hepatology, 4(5):1188-1199, 2021.
[cited by applicant]
Brink, et al., “Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis,” International Journal of Antimicrobial Agents, vol. 33, No. 5, p. 432-436, 2009.
[cited by applicant]
Busch, et al., “Delayed activation of PPAR-[beta]/[delta] improves long-term survival in mouse sepsis: effects on organ inflammation and coagulation,” Innate Immunity, p. 262-273, Retrieved from the Internet: URL:https:…
[cited by applicant]
Cariou, et al., “Effects of the New Dual PPARa/d Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients with Combined Dyslipidemia or Impaired Glucose Metabolism,” Diabetes Care vol. 34, pp. 2008-…
[cited by applicant]
Cariou, et al., “GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes,” Expert Opinion on Investigational Drugs, 23(10):1441-8, 2014.
[cited by applicant]
Chascsa, et al., “Emerging therapies for PBC,” J Gastroenterol, 55(3): 261-272, 2020.
[cited by applicant]
Dohmen, et al., “The Effectiveness of Fenofibrate in Comparison to Bezafibrate for Patients with Asymptomatic Primary Biliary Cirrhosis,” Fukuoka Acta Medica vol. 104, pp. 350-361, 2013.
[cited by applicant]
El-Sisi, et al., “Effects of Three Different Fibrates on Intrahepatic Cholestasis Experimentally Induced in Rats,” PPAR Research vol. 2013, pp. 1-10, 2013.
[cited by applicant]
Galoosian, et al., “Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches” Journal of Clinical and Translational Hepatology vol. 8, pp. 49-60, Jan. 29, 2020.
[cited by applicant]
GENFIT, “FDA and EMA Grant GENFIT's Elafibranor Orphan Drug Designation for Primary Biliary Cholangitis (PBC),” Retrieved online on Jul. 13, 2020.
[cited by applicant]
Ghonem, et al., “Fibrates and Cholestasis,” Hepatology vol. 62, pp. 635-643, 2015.
[cited by applicant]
Halilbasic, et al., “Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases,” Clinical Liver Disease vol. 17, pp. 161-189, 2013.
[cited by applicant]
Hegade, et al., “A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis,” Frontline Gastroenterol;7(3):158-166, Jul. 2016.
[cited by applicant]
Hegade, et al., “Drug treatment of pruritus in liver diseases,” Clin Med (Lond);15(4):351-7, Aug. 2015.
[cited by applicant]
Hegade, et al., “Novel Bile Acid Therapeutics for the Treatment of Chronic Liver Diseases” Therapeutic Advances in Gastroenterology vol. 9, pp. 376-391, 2015.
[cited by applicant]
International Search Report for International Application No. PCT/EP2017/057634, dated Apr. 27, 2017.
[cited by applicant]
International Search Report for International Application No. PCT/EP2018/052163, dated Apr. 19, 2018.
[cited by applicant]
International Search Report for International Application No. PCT/EP2021/052710, dated Apr. 12, 2021.
[cited by applicant]
International Search Report for International Application No. PCT/EP2021/063075, dated Jul. 15, 2021.
[cited by applicant]
International Search Report for International Application No. PCT/EP2021/073473, dated Nov. 3, 2021.
[cited by applicant]
International Search Report for International Application No. PCT/EP2022/062707 mailed Sep. 21, 2022.
[cited by applicant]
International Search Report for International Application No. PCT/EP2022/062710 mailed May 10, 2022.
[cited by applicant]
Khanna, et al., “Novel strategies and therapeutic options for the management of primary biliary cholangitis,” Therapeutic Advances in Gastroenterology, vol. 10(10), pp. 791-803, 2017.
[cited by applicant]
Kita, et al., “Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels,” Journal of Gastroenterology, 41, pp. 686-692 (2006).
[cited by applicant]
Kostapanos, “Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease,” World Journal of Hepatology,vol. 5, No. 9, p. 470. Jan. 1, 2013.
[cited by applicant]
Krones, et al., “Future Medical Treatment of PSC” Current Hepatology Reports vol. 18, pp. 96-106, Feb. 13, 2019.
[cited by applicant]
Kumar, et al, “The PPAR a/g Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease,” Scientific Reports, 10(1):9330, 2020.
[cited by applicant]
Liu, et al., “Early investigational drugs targeting PPAR-a for the treatment of metabolic disease,” Expert Opinion on Investigational Drugs, vol. 24(5); 2015.
[cited by applicant]
Marra, et al, “Thiazolidinedione Treatment Inhibits Bile Duct Proliferation and Fibrosis in a Rat Model of Chronic Cholestasis,” World Journal of Gastroenterology vol. 11, pp. 4931-4938, 2005.
[cited by applicant]
Nicolopoulos, et al., “Chronic Anicteric Intrahepatic Cholestasis Associated with Ankylosing Spondylitis. Beneficial Treatment by Clofibrate,” Digestion vol. 24, pp. 69-72, 1982.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/533,767, dated Feb. 14, 2024.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 18/212,008, dated Oct. 12, 2023.
[cited by applicant]
Ostadhadi, et al., “The role of PPAR-gamma receptor in pruritus,” European Journal of Pharmacology, 762, pp. 322-325, 2015.
[cited by applicant]
Polyzos, et al., “Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis,” Metabolism: Clinical and Experimental, 111S:154203, 2020.
[cited by applicant]
Ratziu, “Novel Pharmacotherapy Options for NASH,” Digestive Diseases and Sciences vol. 61, pp. 1398-1405, Mar. 22, 2016.
[cited by applicant]
Staels, et al., “Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis,” Hepatolog…
[cited by applicant]
Wettstein, et al., “The New-Generation Pan-Peroxisome Proliferator-Activated Receptor Agonist IVA337 Protects the Liver From Metabolic Disorders and Fibrosis,” Hepatology Communications, 1(6):524-537, 2017.
[cited by applicant]
Yamashita, et al., “Pemafibrate, a New Selective PPARa Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases,” Current Atherosclerosis Reports, 22(1):5, 2020.
[cited by applicant]
Yin, et al., “Dose-dependent effects of peroxisome proliferator-activated receptors [beta]/[delta] agonist on systemic inflammation after haemorrhagic shock,” Cytokine, vol. 103, p. 127-132, Mar. 1, 2018.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/506,021, dated Sep. 4, 2024.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/506,029, dated Sep. 5, 2024.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/506,036, dated Sep. 5, 2024.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/505,898, dated Sep. 11, 2024.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/506,013, dated Sep. 11, 2024.
[cited by applicant]
Cited By (1)